Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Canopy Growth Corporation v. GW Pharmaceuticals PLC
Case Number:
6:20-cv-01180
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 01, 2022
GW Pharmaceuticals Beats CBD Patent Infringement Suit
A Texas federal judge has tossed Canopy Growth Corp.'s claims against GW Pharmaceuticals PLC units for allegedly infringing its patented extraction process to make the flagship CBD drug Epidiolex, after the parties agreed that Canopy couldn't prevail on the issue of infringement.
-
March 08, 2021
GW Pharma Wants Out Of Canopy's CBD Patent Dispute
GW Pharmaceuticals has asked a Texas federal court to toss a patent suit brought by Canadian cannabis company Canopy Growth over the flagship CBD drug Epidiolex, arguing that the court has no jurisdiction because the pharmaceutical company does not have enough of a presence in Texas.
-
December 23, 2020
Canopy Slaps GW With Patent Suit Over Flagship CBD Drug
Canadian cannabis company Canopy Growth is accusing GW Pharmaceuticals of ripping off its patented CBD extraction technology to make the flagship CBD drug Epidiolex.